Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Maierthaler, Melanie [VerfasserIn]   i
 Kriegsmann, Mark [VerfasserIn]   i
 Peng, Cike [VerfasserIn]   i
 Jauch, Sarah [VerfasserIn]   i
 Szabo, Akos [VerfasserIn]   i
 Wallwiener, Markus [VerfasserIn]   i
 Rom, Joachim [VerfasserIn]   i
 Sohn, Christof [VerfasserIn]   i
 Schneeweiss, Andreas [VerfasserIn]   i
 Sinn, Peter [VerfasserIn]   i
 Yang, Rongxi [VerfasserIn]   i
 Burwinkel, Barbara [VerfasserIn]   i
Titel:S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer
Verf.angabe:Melanie Maierthaler, Mark Kriegsmann, Cike Peng, Sarah Jauch, Akos Szabo, Markus Wallwiener, Joachim Rom, Christof Sohn, Andreas Schneeweiss, Hans-Peter Sinn, Rongxi Yang, Barbara Burwinkel
E-Jahr:2015
Jahr:August 2015
Umfang:8 S.
Fussnoten:Gesehen am 01.02.2017
Titel Quelle:Enthalten in: Experimental and molecular pathology
Ort Quelle:Orlando, Fla. : Academic Press, 1962
Jahr Quelle:2015
Band/Heft Quelle:99(2015), 1, Seite 180-187
ISSN Quelle:1096-0945
Abstract:Triple-negative breast cancer (TNBC) is a group of very aggressive breast tumours, characterised by lack of expression of oestrogen receptor (ER), progesterone receptor (PR) and erb-b2 receptor tyrosine kinase 2 (ERBB2/HER2). Nevertheless, TNBCs show different clinical characteristics and are very diverse regarding prognostic outcome. So far, only a few prognostic markers for TNBC have been reported that could be helpful for therapeutic stratification. Here we have analysed the expression of S100P and HYAL2 using immunohistochemistry (IHC) in a TNBC cohort of 98 patients with a follow-up for recurrence and death. TNBC patients with high expression of both proteins showed significantly shorter progression-free survival (PFS) (mean PFS = 35.9 months, P = 0.001) compared to TNBC patients with high expression levels of only one of the proteins (mean PFS = 69.4 months) and to TNBC patients with low expression of both proteins (mean PFS = 83.3 months). Moreover, multivariate Cox-regression model showed the combined expression of S100P and HYAL2 as independent prognostic factor for PFS (P = 0.001). The expression of S100P and HYAL2 indicated similar prognostic effect to the overall survival (OS) of TNBC patients. In addition, high expression levels of both S100P and HYAL2 showed significant association with different clinicopathological characteristics, such as more recurrence events (P = 0.004), and higher occurrence of metastasis (P = 0.002). Our study proposes S100P and HYAL2 as potential prognostic markers for TNBC.
DOI:doi:10.1016/j.yexmp.2015.06.010
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext ; Verlag: http://dx.doi.org/10.1016/j.yexmp.2015.06.010
 Volltext: https://www.sciencedirect.com/science/article/pii/S0014480015001288
 DOI: https://doi.org/10.1016/j.yexmp.2015.06.010
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Breast cancer
 HYAL2
 Marker
 Prognosis
 S100P
K10plus-PPN:1553027272
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68079358   QR-Code
zum Seitenanfang